EQ Stock Forecast: Equillium, Inc. Price Predictions for 2026-2027

Last close, 19 Nov 2026
$1.12
+1.82% on the day

The median 12-month analyst price target for Equillium, Inc. is $7. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 52 of 100 as at 18 Nov 2026 — in the upper half.

Market cap
$90.6M
Ticker Nerd rank
52/ 100
Median analyst target
$7.00
Analysts covering
9
Revenue$0.0
Operating income−$5.2M
Net income−$4.7M
Free cash flow−$4.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−15.2%
1M
−9.7%
YTD
−27.7%
1Y
+10.9%
From 52W high
−65.0%
From 52W low
+31.8%
$0.85
$3.20
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Equillium, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 18 Nov 2026
52/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
90
Revisions
68
Momentum
58
Accruals
37
Value
34
Issuance
33
Quality
31
Volatility
20

Growth (90): Sales and profits are climbing, and climbing faster than before.

Volatility (20): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

EQ stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on EQ, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00Jan 26Apr 26Jul 26Oct 26EQHigh $20.00Median $7.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
9
Buy
0
Hold
0
Sell
$4.00
Low
$7.00
Median
$20.00
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
12 Oct 2026Leerink PartnersAssumesOutperform$6.00
4 Sept 2026Roth CapitalReiteratesBuy$12
13 July 2026Piper SandlerInitiatesOverweight$20
2 June 2026Roth CapitalReiteratesBuy—
28 May 2026Leerink PartnersUpgradeOutperform—
28 May 2026Roth CapitalReiteratesBuy—
17 Apr 2026Roth CapitalReiteratesBuy—
16 Apr 2026B. Riley SecuritiesInitiatesBuy—
14 Apr 2026Raymond JamesInitiatesStrong Buy—
13 Mar 2026Roth CapitalInitiatesBuy—
28 Mar 2025Leerink PartnersDowngradeMarket Perform—
1 Nov 2024Jones TradingDowngradeHold—
19 Aug 2024HC Wainwright & Co.ReiteratesBuy—
5 June 2024HC Wainwright & Co.ReiteratesBuy—
17 May 2024HC Wainwright & Co.ReiteratesBuy—
2 Apr 2024HC Wainwright & Co.MaintainsBuy—
26 Dec 2023HC Wainwright & Co.MaintainsBuy—
13 Nov 2023HC Wainwright & Co.MaintainsBuy—
14 Aug 2023Cantor FitzgeraldReiteratesOverweight—
14 Aug 2023HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for EQ.

Market Radar

This page is one stock. Monday covers all of them.

EQ appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

EQ vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 19 Nov 2026, Equillium, Inc. returned +10.9% against +9.2% for the S&P 500, dividends included.

EQ vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250300Jan 26Apr 26Jul 26Oct 26EQS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

EQ analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
4
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
2.3×

Cheaper than 40% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−59.0%

Higher than 20% of US stocks

Return on assets
−34.0%

Higher than 13% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Equillium, Inc. has a market value of $90.6M and an enterprise value of $27.1M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$18.0M.

  • Diluted earnings per share, trailing twelve months: −$0.20.

  • Free cash flow in the twelve months to 30 June 2026: −$20.1M.

  • Shares outstanding: 63.4M.

  • Equillium, Inc. employs 14 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 19 Nov 2026

Data provided by Twelve Data

Peers

EQ and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
EQEquillium, Inc.$90.6M52
ANIXAnixa Biosciences, Inc.$90.9M61
HURATuHURA Biosciences, Inc.$90.1M24
ZURAZura Bio Ltd.$91.6M15
PMVPPMV Pharmaceuticals, Inc.$92.1M59
RANIRani Therapeutics Holdings, Inc.$88.4M63
VANIVivani Medical, Inc.$94.7M44

Take a look at EQ’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Equillium, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about EQ

What is the EQ stock price forecast for 2026-2027?

The median 12-month analyst price target for Equillium, Inc. is $7, with estimates ranging from $4 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is EQ stock a buy right now?

Of the 9 analysts covering Equillium, Inc., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Equillium, Inc. 52 out of 100 across roughly 4,300 US stocks as at 18 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank EQ?

As at 18 Nov 2026, Equillium, Inc. ranks 52 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (90 of 100).

Will EQ stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts is $7, and Ticker Nerd's factor model ranks Equillium, Inc. 52 out of 100 as at 18 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the EQ stock forecast for 2030?

No analyst covering Equillium, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for EQ are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $20 over the next 12 months.

How has EQ stock performed over the past year?

Equillium, Inc. returned +10.9% over the 12 months to 19 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Equillium, Inc. do?

Equillium Inc. is a clinical-stage biotechnology company focused on developing therapies for severe autoimmune and inflammatory disorders with high unmet medical need. Its current pipeline centers on immunology programs designed to modulate disease-driving immune pathways, including monoclonal antibody and cytokine-inhibitor approaches aimed at conditions such as graft-versus-host disease, lupus nephritis, ulcerative colitis, alopecia areata, and other immune-mediated diseases.

Company

About Equillium, Inc.

Equillium Inc. is a clinical-stage biotechnology company focused on developing therapies for severe autoimmune and inflammatory disorders with high unmet medical need. Its current pipeline centers on immunology programs designed to modulate disease-driving immune pathways, including monoclonal antibody and cytokine-inhibitor approaches aimed at conditions such as graft-versus-host disease, lupus nephritis, ulcerative colitis, alopecia areata, and other immune-mediated diseases. The company’s work spans immuno-inflammatory areas across transplant science, gastroenterology, rheumatology, dermatology, oncology, and related specialty care segments. Equillium Inc. operates as a research-driven biopharmaceutical business, advancing novel therapeutic candidates through clinical development and strategic collaborations to address complex diseases where existing treatment options remain limited. Headquartered in La Jolla, California, Equillium Inc. plays a focused role in the biotechnology market as a developer of targeted immune-modulating medicines.

CEO Mr. Bruce Steel · 14 employees · United States · https://www.equilliumbio.com